Reduction of Burn Progression and Scar Contracture with Cytokine-Neutralizing Gels

Award Information
Agency:
Department of Defense
Amount:
$150,000.00
Program:
SBIR
Contract:
W81XWH-13-C-0050
Solitcitation Year:
2012
Solicitation Number:
2012.2
Branch:
Defense Health Program
Award Year:
2013
Phase:
Phase I
Agency Tracking Number:
H122-016-0039
Solicitation Topic Code:
DHP12-016
Small Business Information
Washburn Therapeutics, Inc.
6743 Wilkins Ave., Pittsburgh, PA, -
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
803136758
Principal Investigator
 Newell Washburn
 President
 (412) 908-1309
 newell.washburn@gmail.com
Business Contact
 Newell Washburn
Title: President
Phone: (412) 908-1309
Email: newell.washburn@gmail.com
Research Institution
 Stub
Abstract
Washburn Therapeutics Inc. is developing biologically active gels that control inflammation by selectively neutralizing pro-inflammatory cytokines based on a technology being licensed exclusively by the company from Carnegie Mellon University. Preliminary results demonstrated that conjugates of antibodies against tumor necrosis factor-alpha and hyaluronic acid were able to reduce secondary necrosis in a partial-thickness rat burn model by 70%. This SBIR Phase I will focus on treating partial-thickness burns to test of the safety and efficacy of the technology in preventing extensive tissue necrosis following burn and measuring subsequent scar contraction in the rat burn model. The hypothesis of this research program is that prevention of burn progression through local control of inflammatory responses will improve healing outcomes. Early therapeutic intervention could make a significant impact in burn treatment.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government